Compare GAB & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAB | TRVI |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | 2019 |
| Metric | GAB | TRVI |
|---|---|---|
| Price | $5.54 | $14.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $21.55 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 10.91% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.28 | $5.38 |
| 52 Week High | $6.37 | $16.12 |
| Indicator | GAB | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 51.15 |
| Support Level | $5.48 | $10.07 |
| Resistance Level | $6.22 | $16.12 |
| Average True Range (ATR) | 0.09 | 0.80 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 16.36 | 40.11 |
Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.